Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GlaxoSmithKline

GSK Glaxo Smith clinical programs — 205 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

GSK Glaxo Smith projects

205 ClinicalTrials.gov programs sponsored by GSK Glaxo Smith.

GSK Glaxo Smith has 205 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

205 programs

Clinical programs

Page 2 of 5

  1. Gepotidacin

    GlaxoSmithKline

    Urinary Tract Infections

    phase 3 small molecule completed

    1 trial

  2. Glipizide

    GlaxoSmithKline

    Atherosclerosis

    phase 3 small molecule completed

    1 trial

  3. Gynaecological follow-up

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 other completed

    1 trial

  4. H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  5. Hepatitis B adjuvanted vaccine

    GlaxoSmithKline

    Hepatitis B

    phase 3 mab completed

    1 trial

  6. Human rotavirus liquid vaccine

    GlaxoSmithKline

    Infections, Rotavirus

    phase 3 mab completed

    1 trial

  7. Infanrix hexa™

    GlaxoSmithKline

    Poliomyelitis

    phase 3 mab completed

    1 trial

  8. Infanrix-IPV+Hib™

    GlaxoSmithKline

    Acellular Pertussis

    phase 3 mab completed

    1 trial

  9. Influenza A (H5N1) Virus monovalent vaccine

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  10. Influenza vaccine GSK1562902A Formulation 1

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  11. Influenza vaccine GSK2321138A

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  12. Lapatinib

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule completed

    1 trial

  13. MEPOLIZUMAB

    GlaxoSmithKline

    Hypereosinophilic syndrome (HES)

    phase 3 small molecule active

    1 trial

  14. Mencevax ACWY

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    1 trial

  15. Meningococcal vaccine GSK134612

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    2 trials

  16. Nimenrix

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    1 trial

  17. Niraparib

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  18. Niraparib Placebo Tablets

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  19. Placebo

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 mab completed

    1 trial

  20. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  21. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  22. RSV MAT

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 mab terminated

    1 trial

  23. Rosiglitazone Extended Release 2mg

    GlaxoSmithKline

    Alzheimer's Disease

    phase 3 small molecule completed

    1 trial

  24. SB-497115-GR 12.5mg

    GlaxoSmithKline

    Chronic Idiopathic Thrombocytopenic Purpura

    phase 3 small molecule completed

    1 trial

  25. Salbutamol HFA-134a

    GlaxoSmithKline

    Asthma

    phase 3 small molecule completed

    1 trial

  26. Tafenoquine

    GlaxoSmithKline

    Malaria, Vivax

    phase 3 small molecule completed

    2 trials

  27. Tritanrix-HepB/Hib-MenAC

    GlaxoSmithKline

    Whole Cell Pertussis

    phase 3 mab completed

    1 trial

  28. Tritanrix™-HepB/Hiberix™ Kft.

    GlaxoSmithKline

    Whole Cell Pertussis

    phase 3 mab completed

    1 trial

  29. albiglutide + insulin glargine

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 mab completed

    1 trial

  30. alosetron

    GlaxoSmithKline

    Irritable Colon

    phase 3 small molecule completed

    1 trial

  31. denosumab

    GlaxoSmithKline

    Osteoporosis, Postmenopausal

    phase 3 small molecule completed

    1 trial

  32. dutasteride 0.5mg once daily for 4 years

    GlaxoSmithKline

    Prostatic Hyperplasia

    phase 3 small molecule completed

    1 trial

  33. eltrombopag

    GlaxoSmithKline

    Hepatitis C, Chronic

    phase 3 small molecule completed

    1 trial

  34. eltrombopag

    GlaxoSmithKline

    Purpura, Thrombocytopaenic, Idiopathic

    phase 3 small molecule completed

    2 trials

  35. fluticasone furoate/vilanterol

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    1 trial

  36. lamotrigine, 300 mg/day

    GlaxoSmithKline

    Epilepsy, Partial

    phase 3 small molecule completed

    1 trial

  37. lapatinib

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule completed

    1 trial

  38. placebo to match albiglutide

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  39. 0.9% Sodium Chloride Injection

    GlaxoSmithKline

    Non-alcoholic Fatty Liver Disease

    phase 2 small molecule active

    1 trial

  40. 114055

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  41. 200908

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  42. 206882

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 2 other active

    1 trial

  43. 208887

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  44. 209628

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 other active

    1 trial

  45. 213403

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  46. 213824

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  47. 217043

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  48. 219231

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does GSK Glaxo Smith have?

205 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.